Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations
A legfontosabb adatok
- Ki végzi
- Vanderbilt University Medical Center
- Hol
- Nashville (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Visszavonva
- Fázis
- 2. fázis
- Kezdés
- 2025. szept. 1.
- Várható befejezés
- 2029. szept. 5.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Montelukast Oral Granules
- A regiszteradat frissítve
- 2024. november 18.
- Miért állt le
- Unfunded
Ki vehet részt
- Életkor
- 5 év – 17 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Age 5 to 17 years, inclusive
- Parental report of asthma diagnosis by a health care provider
- At least one previous wheezing episode treated with albuterol
- Moderate or severe acute asthma exacerbation measured using the validated AAIRS bedside asthma severity score
Ki nem vehet részt
- Prior study enrollment
- Gastroesophageal reflux requiring acid-blocking medication; and
- Prior use of an LTRA (e.g., montelukast)
- Chronic lung disease other than asthma
- Acute or chronic liver disease
- Allergy to montelukast
- Tuberculosis
- History of prematurity less than 34 weeks gestational age
- Presence of tracheostomy
- Use of noninvasive ventilation at home
- Need for immediate airway intervention (e.g., endotracheal intubation or noninvasive ventilation)
- Pregnancy
Helyszínek itt: Egyesült Államok
- Vanderbilt Children's HospitalNashville, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Objective: To determine the extent to which high-dose (30mg) oral montelukast, added to standard treatment in children with moderate and severe acute exacerbations improves outcomes.
A teljes eredeti leírásKevesebb
Central Hypothesis: High-dose oral montelukast, added to standard treatment in children aged 5 to 17 years with moderate and severe acute asthma exacerbations, rapidly improves lung function, clinical severity, hospitalization rate and 72-hour symptom burden.
Secondary Hypotheses:
1. There are greater effects of high-dose oral montelukast on lung function and on the secondary outcomes in the presence of respiratory viral detection or leukotriene-mediated inflammation; and 2. There is an interaction between viral detection and urinary leukotriene 4 level with treatment-response.
Design: A two-arm, parallel randomized controlled trial of high-dose oral montelukast versus identical placebo, as add-on to standard treatment, in children aged 5 to 17 years with moderate and severe acute asthma exacerbations.
Intervention: High-dose oral montelukast added to standard treatment in comparison with standard treatment as the 2nd treatment-allocation arm.
Primary and Important Secondary Endpoints: For the Primary Aim, the primary outcome measure to be compared between arms will be change of %-predicted airway resistance by impulse oscillometry (IOS) at 5Hz (%R5) at 2 hours after treatment initiation. Secondary outcomes will include improvement of %-predicted FEV1 (%FEV1), clinical severity measured using the validated Acute Asthma Intensity Research Score (AAIRS), hospitalization rate, and 72 hour symptom burden using the Pediatric Asthma Caregiver Diary (PACD). For the Secondary Aim, the investigators will determine (1) The effects of high-dose oral montelukast on lung function and on our secondary outcomes in the presence of nasal viruses and of greater leukotriene-mediated inflammation; and (2) The degree of interaction between viral detection and urinary leukotriene E4 (LTE4) level with treatment-response.
Laboratory evaluations: The primary outcome (change of %R5) and select secondary outcomes (%FEV1, AAIRS, LTE4) will be measured before and again at 2 hours after treatment initiation. The other secondary outcomes will be measured at the time of hospitalization decision-making by the clinical team (hospitalization rate) or at 72-hours after treatment initiation (PACD).
A vizsgálat 2 csoportja
- High-dose Montelukast Oral GranulesA vizsgált kezelés
30 mg (high-dose) oral montelukast granules mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
Kezelés: Montelukast Oral Granules
- PlaceboPlacebo, összehasonlításként
Identical placebo mixed in apple sauce will be administered orally immediately after informed consent and assent are obtained.
Kezelés: Montelukast Oral Granules
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2024. november 18.